DaVita Inc. ($DVA) Stock Forecast: Down 5.2% Today

What is DaVita Inc.?

DaVita (NYSE: DVA) is a healthcare company specializing in kidney care services, including dialysis and related treatments. The company focuses on patient care, community health, and corporate citizenship.

Why is DaVita Inc. going down?

DVA stock is down 5.2% on Mar 13, 2026 14:26

• DaVita's stock experienced a bearish movement likely due to market skepticism concerning downbeat forecasts and concerns over the company's business model and financial performance.
• Despite DaVita's strong Q4 earnings and optimistic FY2026 guidance, negative sentiment from Wall Street analysts regarding declining sales and other issues may have contributed to the stock's decline.
• The market may be reacting to the overall cautious outlook on DaVita's future growth potential, as concerns were raised about unpopular stocks and their underlying challenges.
• The bearish movement could also be influenced by broader market trends or sector-specific factors impacting healthcare companies, leading investors to reevaluate their positions in DaVita.

DVA Price Chart

DVA Technical Analysis

DVA News

Senior operator Ensign Group to discuss growth strategy at Oppenheimer event

The Ensign Group (NASDAQ: ENSG) is scheduled to present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 19, 2026, at 10:40 a.m. Eastern Time. Key executives including CEO Barry Port will discuss the company's operations, growth strategy, and related information, with a live webcast and archived replay available for 90 days. The announcement comes after the company reported strong 2025 financial results and expanded its portfolio to 378 healthcare facilities across 17 states through recent acquisitions.

https://www.stocktitan.net/news/ENSG/the-ensign-group-to-present-at-the-oppenheimer-36th-annual-osuq1roq8chp.html

Quest Diagnostics (DGX) Down 4.2% Since Last Earnings Report: Can It Rebound?

Quest Diagnostics (DGX) shares have fallen 4.2% since its last earnings report, underperforming the S&P 500. Despite this, the company's Q4 2025 earnings and revenues beat estimates, and its full-year 2026 guidance is strong. Analysts have shown an upward trend in estimate revisions, with the stock currently holding a Zacks Rank #3 (Hold).

https://sg.finance.yahoo.com/news/quest-diagnostics-dgx-down-4-153004225.html

DaVita Releases Annual Community Care Report, Highlights Achievements in Corporate Citizenship

DaVita (NYSE: DVA) has released its annual Community Care report, detailing significant progress across its five strategic ESG focus areas: Patient Care, Teammate Engagement, Environmental Stewardship, Healthy Communities, and Leading with Integrity and Accountability. The report highlights achievements from calendar year 2024, including a record number of kidney transplants, widespread patient education, environmental savings, and substantial volunteer hours. DaVita's CEO, Javier Rodriguez, emphasized the company's commitment to improving community health and patient experience as it reflects on 25 years of care.

https://csrwire.com/press-release/davita-releases-annual-community-care-report-highlights-achievements/

Dimensional Fund Advisors LP Grows Holdings in DaVita Inc. $DVA

Dimensional Fund Advisors LP increased its stake in DaVita Inc. by 8.8% in Q3, now owning 1,085,593 shares valued at approximately $144.23 million. Other institutional investors also adjusted their holdings in DaVita. The company reported strong Q4 earnings, exceeding analyst expectations, and provided optimistic FY2026 EPS guidance.

https://www.marketbeat.com/instant-alerts/filing-dimensional-fund-advisors-lp-grows-holdings-in-davita-inc-dva-2026-03-11/

3 Unpopular Stocks That Fall Short

This article identifies three unpopular stocks—Dine Brands (DIN), DaVita (DVA), and FTI Consulting (FCN)—that Wall Street analysts have issued downbeat forecasts for, suggesting problems with their business models or financial performance. For each company, it highlights specific reasons for caution, such as declining sales, efficiency issues, high debt, or muted growth. The author suggests that despite market skepticism, these concerns are well-placed, and better investment opportunities exist.

https://finviz.com/news/335791/3-unpopular-stocks-that-fall-short

Trending Today

DaVita Inc. Price History

05.01.2026 - DVA Stock was up 5.4%

• DaVita's stock price surged after the company announced an impressive 2026 adjusted EPS forecast, exceeding market expectations and showcasing strong growth potential.
• Analysts raised their price target for DaVita, citing confidence in the company's future performance and outlook, further boosting investor sentiment.
• The strategic expansion initiatives, such as the partnership with Ares Management and Elara Caring for a kidney-focused home-based care model, have also contributed to the positive market movement.
• Despite potential challenges like the end of ACA subsidies, DaVita's focus on reducing debt, share buybacks, and operational improvements have instilled optimism among investors, leading to the bullish trend in the stock price.

06.01.2026 - DVA Stock was down 5.4%

• Following a recent increase in stock price, DaVita Inc. (DVA) encountered a considerable downward trend today, potentially influenced by investor uncertainty surrounding future earnings stability.
• The apprehensive outlook on DVA might have been impacted by its earnings decrease over the past year, despite optimistic projections for robust yearly growth over the next three years.
• Although the National Pension Service acquired a new share in DVA in the third quarter and the market responded positively to Q4 earnings, concerns regarding reimbursement, regulatory shifts, and financial uncertainties persisted, contributing to the downward movement in the market today.

09.00.2026 - DVA Stock was down 1.8%

• DaVita HealthCare Partners stock hit a 52-week low at $112.53, reflecting a significant 24.81% decline over the past year.
• Despite trading below its Fair Value and having a strong free cash flow yield, the stock has been under pressure due to missing Q3 2025 earnings expectations, reporting an EPS of $2.51 against a projected $3.23.
• The company's aggressive share buyback program and the addition of a new board member, Gregory J. Moore, from Tolion Health AI, might indicate strategic efforts to navigate through the challenging market conditions.
• The extension of the Updated Product Purchase Agreement with Rockwell Medical with a price increase could potentially provide a slight boost to DaVita's revenue stream, but the overall market sentiment remains bearish for now.

14.00.2026 - DVA Stock was down 5.8%

• On January 13, DaVita Inc. (DVA) experienced a notable decline of 3.83%, reaching an intraday low. Several factors could have contributed to this movement:
• The stock performed poorly compared to its industry peers, marking its third consecutive day of losses as major market indices like the S&P 500 and Dow Jones Industrial Average also saw declines.
• DaVita's stock reached a 52-week low, signaling a 33.52% drop over the past year. Despite analysts deeming it undervalued, the recent earnings disappointments and industry headwinds have fueled negative market sentiment.
• Analysts hold a bullish long-term perspective, setting price targets as high as $186. However, current market dynamics may be swayed by concerns surrounding financial performance and broader sectoral challenges.

13.00.2026 - DVA Stock was down 5.0%

• DaVita's stock plummeted to a 52-week low, reflecting a negative investor sentiment.
• Despite analysts deeming the stock undervalued and displaying strong financial indicators like a low P/E ratio and high free cash flow yield, a recent earnings disappointment likely contributed to the decline in stock value.
• The renewal of the supply agreement with Rockwell Medical, coupled with a price hike, could have sparked worries about DaVita's cost efficiency and future profitability, affecting investor trust.
• DaVita's shift towards a comprehensive kidney care platform, while holding potential long-term benefits, may be clouded by uncertainties over its implementation and short-term financial consequences, further fueling the negative market sentiment.

12.01.2026 - DVA Stock was up 5.5%

• DaVita's stock experienced a strong bullish movement due to several key factors:
• Overcoming skepticism related to GLP-1 drugs and successfully transitioning to a value-based integrated kidney care model.
• Aggressive share buybacks and a clarified regulatory environment boosting investor confidence.
• Strong financial performance, including profitability in the Integrated Kidney Care segment, driving the stock to new all-time highs.
• The positive outlook for DaVita is further supported by Wall Street analysts' consensus "Hold" rating, with UBS maintaining a "Buy" rating and a $190 price target, indicating a potential upside of 34.9%.
• The company's ability to deliver better-than-expected Q4 2025 results, surpassing analyst expectations for revenue and non-GAAP profit, has further fueled investor optimism and contributed to the bullish market movement.

13.02.2026 - DVA Stock was down 5.2%

• DaVita's stock experienced a bearish movement likely due to market skepticism concerning downbeat forecasts and concerns over the company's business model and financial performance.
• Despite DaVita's strong Q4 earnings and optimistic FY2026 guidance, negative sentiment from Wall Street analysts regarding declining sales and other issues may have contributed to the stock's decline.
• The market may be reacting to the overall cautious outlook on DaVita's future growth potential, as concerns were raised about unpopular stocks and their underlying challenges.
• The bearish movement could also be influenced by broader market trends or sector-specific factors impacting healthcare companies, leading investors to reevaluate their positions in DaVita.

04.01.2026 - DVA Stock was up 6.6%

• Collaborating with Elara Caring to expand home-based care options for dialysis patients has sparked investor optimism and signaled a shift towards integrated care models and increased access to in-home treatment.
• The company's strong Q4 results, exceeding revenue and earnings expectations, coupled with a positive forecast for 2026, have increased investor confidence and boosted the stock price.
• DaVita's share repurchase and optimistic guidance for the upcoming year demonstrate confidence in its strategic direction and potential for sustained growth, contributing to the current bullish market trend.

04.01.2026 - DVA Stock was up 9.2%

• Company's price target was increased to $190 from $186 by UBS, noting strong 2026 guidance with anticipated growth in operating income and EPS, as well as benefits from the Elara Caring investment.
• Partnership with Elara Caring presents a novel approach to kidney and home care services, potentially broadening in-home health options for dialysis patients and promoting more integrated care models.
• Exceeding expectations, DaVita reported impressive fourth-quarter results with revenue hitting $3.62 billion and adjusted profit per share at $3.40, driving a substantial stock surge.
• Exceptional 2026 adjusted earnings per share forecast of $14.30, surpassing previous analyst estimates, has increased investor confidence in DaVita's future outlook.

03.01.2026 - DVA Stock was up 23.2%

• DaVita delivered impressive Q4 2025 earnings, exceeding projections with an EPS of $3.40 and offering a positive outlook for 2026. This robust financial performance likely influenced the stock's upward trajectory.
• Institutional investors, such as Mirae Asset Global Investments Co. Ltd., notably enlarged their position in DaVita, demonstrating their faith in the company's future prospects.
• While concerns exist regarding slowing revenue growth and decreasing margins, DaVita's targeted efforts to enhance patient care and profitability appear to have garnered favor among investors, propelling the stock upwards.
• The prevailing positive sentiment in the market, as evidenced by the increase in S&P 500 futures, may have also contributed to the further rise in DaVita's stock value.

03.01.2026 - DVA Stock was up 20.2%

• DaVita's robust Q4 performance and positive 2026 guidance bolstered investor confidence, leading to a 25% increase in its stock value.
• The 14.2% decline in short interest suggests a change in sentiment toward the company after its solid financial showing.
• Enhanced margins, driven by increased revenue per treatment and strategic acquisitions, contributed to the favorable market response and stock price appreciation.
• DaVita's commitment to enhancing patient care, reducing mortality rates, and pursuing future growth through strategic moves, as highlighted in the earnings call, further reinforced investor confidence in the company's future prospects.

07.00.2026 - DVA Stock was down 3.8%

• DaVita HealthCare Partners stock hit a 52-week low due to a 24.81% decline over the past year, exacerbated by a recent earnings miss in Q3 2025.
• Despite trading below its Fair Value and having a strong free cash flow yield, the company's challenges in the market and the earnings disappointment contributed to the bearish movement.
• The extension of the supply agreement with Rockwell Medical, including a price adjustment, may have also impacted investor sentiment, adding to the overall negative outlook for DaVita HealthCare Partners.
• The addition of a former Microsoft and Google executive to Tolion Health AI's Board could signal potential strategic shifts in the industry, but it did not provide enough positive momentum to offset the stock's downward trend.